Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb;41(2):477-481.
doi: 10.1007/s10875-020-00910-7. Epub 2020 Nov 19.

Eculizumab-Responsive Adult Onset Protein Losing Enteropathy, Caused by Germline CD55-Deficiency and Complicated by Aggressive Angiosarcoma

David Hagin #  1 , Dror Lahav #  2 , Tal Freund  3 , Sivan Shamai  4 , Eli Brazowski  5 , Sigal Fishman  6 , Alina Kurolap  7 , Hagit Baris Feldman  8 , Mordechai Shohat  9 , Ophira Salomon  10
Affiliations
Case Reports

Eculizumab-Responsive Adult Onset Protein Losing Enteropathy, Caused by Germline CD55-Deficiency and Complicated by Aggressive Angiosarcoma

David Hagin et al. J Clin Immunol. 2021 Feb.
No abstract available

PubMed Disclaimer

References

    1. Ozen A, Comrie WA, Ardy RC, Dominguez Conde C, Dalgic B, Beser OF, et al. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis. N Engl J Med. 2017;377(1):52–61. - DOI
    1. Kurolap A, Eshach-Adiv O, Hershkovitz T, Paperna T, Mory A, Oz-Levi D, et al. Loss of CD55 in eculizumab-responsive protein-losing enteropathy. N Engl J Med. 2017;377(1):87–9. - DOI
    1. Kurolap A, Eshach Adiv O, Hershkovitz T, Tabib A, Karbian N, Paperna T, et al. Eculizumab is safe and effective as a long-term treatment for protein-losing enteropathy due to CD55 deficiency. J Pediatr Gastroenterol Nutr. 2019;68(3):325–33. - DOI
    1. Wilson GC, Lluis N, Nalesnik MA, Nassar A, Serrano T, Ramos E, et al. Hepatic angiosarcoma: a multi-institutional, international experience with 44 cases. Ann Surg Oncol. 2019;26(2):576–82. - DOI
    1. Vikkula M, Boon LM, Carraway KL, Calvert JT, Diamonti AJ, Goumnerov B, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996;87(7):1181–90. - DOI

MeSH terms

LinkOut - more resources